36th BMCS Spring Symposium on Medicinal Chemistry
Event
36th BMCS Spring Symposium on Medicinal Chemistry
Dates
Thursday, 24th April 2025
Place
Fielder Centre, Hatfield, UK
Important links and downloads
X hashtag – #HatfieldMedChem25
Please click here to download the first announcement poster
Synopsis
Known colloquially as the “Hatfield MedChem” meeting, this is a highly successful, long-standing, one-day meeting that runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics at the forefront of drug discovery. The meeting aims to be informal and interactive, and is ideal for all those working in medicinal chemistry and drug discovery more widely.
Registration:
Registration is open, please click here to register!
RSC Member £150
Non Member £200
RSC Student Member £75
Student Non-Member £98
RSC Unemployed Member £45
Unemployed Non-Member £75
Retired Member £45
Call for Abstracts:
Abstract submission is now open, please click here to access the abstract template. All submissions should be emailed to events@hg3.co.uk
Deadline for oral submissions – Friday 15th November, 2024.
Deadline for poster submissions – Friday 7th February, 2025
Exhibitor Package (£600.00) *Fully booked*
- A table and chairs
- Access to electricity and wi-fi
- Logo inclusion in pdf of delegate handbook and rolling slides
- Promotional page in the pdf delegate handbook
- One stand personnel with access to technical sessions
Please note that all exhibition stands are now fully booked, but there is still the opportunity to be a sponsor for the meeting. Please click here to sponsor the meeting.
Confirmed Exhibitors:
Confirmed Sponsors
Confirmed Speakers
Gilles Ouvry, NRG
Discovery of orally available, brain penetrant mPTP blockers
Maxime Rouah, GSK
Advanced High-Throughput Synthesis Strategies for Evaluating Novel E3 Ligases for Targeted Protein Degradation Applications
Julien Michel, University of Edinburgh
Therapeutic Opportunities for Fatty Liver Disease with Isoform-selective Cyclophilin Inhibitors
Barbara Forte, Dundee Drug Discovery Unit
Optimisation of lysyl-t-RNA synthetase inhibitors as antimalarials
Steven Howard, Astex
Discovery of ASTX295: A bone-marrow sparing MDM2 Antagonist. From concept to clinic
James Reuberson, UCB
The Discovery of an Orally Bioavailable Benzimidazole-derived Small Molecule Inhibitor of IL-17A
Coura Diene, AstraZeneca
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate
Organising Committee
Adrian Hall, UCB (Chair)
Douglas Williamson, Nxera Pharma (Treasurer)
David Hirst, MSD
Alison Jones, Charles River
Secretariat Contact and Further Information
Hg3 Conferences Ltd
+44 (0)1423 529333
E-mail

